European Biotech Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in Amsterdam, the Netherlands.
IPO Year: 2021
Exchange: NASDAQ
Website: lspvc.com/ebac
| Date | Price Target | Rating | Analyst |
|---|
Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indications such as glaucoma, affecting growing patient populationsNet proceeds expected to support advanced clinical pipeline of multiple innovative product candidates with near term potential value catalysts, potentially including the first topical eye-drop for DME, the fir
SC 13G - European Biotech Acquisition Corp. (0001841258) (Subject)
SC 13G - European Biotech Acquisition Corp. (0001841258) (Subject)
SC 13G/A - European Biotech Acquisition Corp. (0001841258) (Subject)
SC 13G/A - European Biotech Acquisition Corp. (0001841258) (Subject)
SC 13G - European Biotech Acquisition Corp. (0001841258) (Subject)
SC 13G/A - European Biotech Acquisition Corp. (0001841258) (Subject)
Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indications such as glaucoma, affecting growing patient populations Net proceeds expected to support advanced clinical pipeline of multiple innovative product candidates with near term potential value catalysts, potentially including the first topical eye-drop for DME, the
15-12G - European Biotech Acquisition Corp. (0001841258) (Filer)
25-NSE/A - European Biotech Acquisition Corp. (0001841258) (Subject)
8-K - European Biotech Acquisition Corp. (0001841258) (Filer)
10-K - European Biotech Acquisition Corp. (0001841258) (Filer)
8-K - European Biotech Acquisition Corp. (0001841258) (Filer)
DEFA14A - European Biotech Acquisition Corp. (0001841258) (Filer)
8-K - European Biotech Acquisition Corp. (0001841258) (Filer)
DEFM14A - European Biotech Acquisition Corp. (0001841258) (Filer)
425 - European Biotech Acquisition Corp. (0001841258) (Subject)
8-K - European Biotech Acquisition Corp. (0001841258) (Filer)